SPONSOR:PRINTER'S NO.

Sen.2984 THE GENERAL ASSEMBLY OF PENNSYLVANIA HOUSE RESOLUTION Session of No.

Poore430 &2026 Rep.INTRODUCED BY DELLOSO, HOHENSTEIN, VENKAT, HILL-EVANS, WAXMAN, RIVERA, McNEILL, FREEMAN, PROBST, SANCHEZ, BURGOS AND CEPEDA- FREYTIZ, MARCH 11, 2026 REFERRED TO COMMITTEE ON HEALTH, MARCH 11, 2026 A RESOLUTION DesDyskinesia Awareness Week" in Pennsylvania.

Minor-Brownas Sens."Tardive WHEREAS, Serious mental illnesses such as bipolar disorder, major depressive disorder and schizophrenia often require treatment with antipsychotic medications for effective management, and antipsychotic medication prescribing rates continue to rise;

Hansen,and Pinkney;WHEREAS, While prolonged use of antipsychotic medication may be essential for the treatment of certain conditions, it is associated with tardive dyskinesia (TD), a condition marked by uncontrollable, abnormal and repetitive movements of the face, torso, limbs or extremities;

Reps.and WHEREAS, An individual is at higher risk of TD if the individual:

Briggs(1) King,is Griffith,55 K.years of age or older, Black or a woman;

Johnsonor DELAWARE(2) STATEhas SENATEa 152ndmood GENERALdisorder, ASSEMBLYsubstance SENATEuse CONCURRENTdisorder, RESOLUTIONintellectual NO.disability, central nervous system injury or high cumulative antipsychotic medication exposure;

33and DESIGNATINGWHEREAS, MAYApproximately 1–7,60% 2023,of ASthe “TARDIVEestimated DYSKINESIA800,000 AWARENESSUnited WEEK”States INadults DELAWARE.living with TD remain undiagnosed;

and WHEREAS, MayEven ismild NationalTD Mentalsymptoms Healthcan Awarenessbe Month;stigmatizing and impair physical, social and emotional well-being, underscoring the urgency of early screening, detection and intervention;

and WHEREAS, TardiveThe DyskinesiaAmerican isPsychiatric aAssociation movementrecommends disorderroutine thatTD disproportionatelyscreening affectsin peopleits beingclinical treatedguidelines for chronicantipsychotic mentaltreatment; health conditions, including schizophrenia, bipolar disorder, and severe depression;

and WHEREAS, ongoingIndividuals treatmenttreated with prescription antipsychotic medicationsmedication hasor manyexperiencing benefitsabnormal formovements thoseshould withconsult thesetheir health care providers to assess TD risk, receive TD screenings and otherdetermine mentalappropriate illnesses;treatment;

and WHEREAS, antipsychoticTreatments medicationsapproved mayby leadthe toUnited TardiveStates DyskinesiaFood inand oneDrug outAdministration for TD can provide options for symptom management and an improved quality of everylife fourfor patientsmany receivingindividuals long-termliving treatment;with TD;

and WHEREAS, TardiveThe DyskinesiaHouse isof characterizedRepresentatives byencourages random,TD involuntary,screening education and uncontrollableawareness movementsfor ofhealth musclescare inproviders, thepatients face,and trunk,care partners to help ensure that patients who are prescribed antipsychotic medication receive care and extremities;support that aligns with clinical best practices, including regular TD screenings;

andtherefore WHEREAS,be Tardiveit DyskinesiaRESOLVED, canThat developthe longHouse afterof aRepresentatives persondesignate beginsthe treatment,week orof evenMay after3 thethrough discontinuation9, of2026, treatmentas with"Tardive antipsychoticDyskinesia medications;Awareness Week" in Pennsylvania;

and WHEREAS,be onceit Tardivefurther RESOLVED, That the House of Representatives, in recognition and support of "Tardive Dyskinesia develops,Awareness itWeek," isemphasize oftenthe permanent;importance of early detection and intervention to improve 20260HR0430PN2984 - 2 - outcomes for individuals living with mental health conditions and prescribed antipsychotic medication and support efforts to raise awareness about the causes and symptoms of TD and the importance of routine TD screening.

and20260HR0430PN2984 WHEREAS,- over3 600,000- Americans have been diagnosed with Tardive Dyskinesia, with many more suffering, although unaware of the cause or having been misdiagnosed;

and WHEREAS, scientific breakthroughs and years of research have allowed the Food and Drug Administration to recently approve two new treatments for the symptoms related to Tardive Dyskinesia;

and WHEREAS, it is important to raise further awareness of this disorder throughout the community.

NOW, THEREFORE:

BE IT RESOLVED by the Senate of the 152nd General Assembly of the State of Delaware, the House of Representatives concurring therein, that the week of May 1-7, 2023, is designated as “Tardive Dyskinesia Awareness Week” in the State of Delaware.

BE IT FURTHER RESOLVED that this General Assembly encourages all Delawareans to become better informed about Tardive Dyskinesia.

SD :

AVP :

CBK Page 1 of 2 Released:

04/05/2023 02:16 PM SYNOPSIS This resolution designates the week of May 1-7, 2023, as "Tardive Dyskinesia Awareness Week" in Delaware.

Author:

Senator Poore SD :

AVP :

CBK Page 2 of 2 Released:

04/05/2023 02:16 PM 4761520022